Table 4.
Glucose-lowering efficacy of sodium-glucose co-transporter-2 inhibitors
| Molecule (duration of study) | Parameter | Monotherapy | Combination with other oral anti-diabetic drugs | As add-on to insulin | ||||
|---|---|---|---|---|---|---|---|---|
| Initial combination with Met | With Met | With SU | With Met + SU | With Met + TZD | ||||
| Canagliflozin 300 mg (26-week study) | HbA1c (%) | −1.03 | – | −0.94 | −0.79 | −1.06 | −1.03 | −0.72 |
| FPG (mg/dl) | −35 | – | −27 | – | −31 | −33 | −25 | |
| PPG (mg/dl) | −59 | – | −48 | – | – | – | – | |
| Dapagliflozin 10 mg (24-week study) | HbA1c (%) | −0.9 | −2.0 | −0.8 | −0.8 | −1.0 | −0.4 | −0.9 |
| FPG (mg/dl) | −28.8 | −60.4 | −23.5 | −28.5 | −29.6 | −24.1 | −21.7 | |
| PPG (mg/dl) | – | – | – | −60.6 | −67.5 | – | – | |
| Ipragliflozin 300 mg (24 week study) | HbA1c (%) | −1.29 | – | −0.48 | −1.14 | −0.88 | – | – |
| FPG (mg/dl) | −39.4 | – | – | −38 | −41 | – | – | |
FPG fasting plasma glucose, HbA1c glycated hemoglobin, Met metformin, MetXR metformin extended release, PPG post-prandial plasma glucose, SU sulfonylurea, TZD thiazolidinedione